[Disseminated intravascular coagulation (DIG) with massive hyperfibrinolysis in metastatic uterine cancer. Observations on the effects on the coagulopathy of various treatments (a case report)].
We report on a 64-year-old patient with a recurrent endometrial carcinoma which was associated with disseminated intravascular coagulation (DIC) and excessive hyperfibrinolysis. The patient presented with severe bleeding due to hypofibrinogenemia. Fibrin degradation products were excessively elevated and there were also increased levels of activation markers of coagulation. Free plasmin was demonstrated in the circulation and alpha 2-antiplasmin was almost completely depleted. No increase in t-PA or u-PA level was demonstrated. Antifibrinolytic treatment led to a decrease of fibrin degradation products, but to an increase of activation markers of coagulation and was not associated with an increase of fibrinogen. Combination chemotherapy led to a rapid decrease of activation markers of coagulation and a sustained increase of fibrinogen. The beneficial effects on DIC/hyperfibrinolysis occurred despite the absence of any measurable effect of chemotherapy on the tumour. The patient finally died due to progression of the tumour, but without recurrence of the DIC/hyperfibrinolysis.
Weltermann
A
A
Abteilung für Hämatologie/Hämostaseologie, Universitätsklinik Innere Medizin I, Osterreich.
Mitterbauer
G J
GJ
Mitterbauer
M
M
Hattey
E
E
Speiser
W
W
Gisslinger
H
H
Knöbl
P
P
Eichinger
S
S
D000230:Adenocarcinoma / Q000097:blood* / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004211:Disseminated Intravascular Coagulation / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy*; D016889:Endometrial Neoplasms / Q000097:blood* / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism*; D005342:Fibrinolysis; D006801:Humans; D008875:Middle Aged; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000097:blood; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood; D000093542:Gemcitabine
D015415:Biomarkers; D014408:Biomarkers, Tumor; D005338:Fibrin Fibrinogen Degradation Products; D003841:Deoxycytidine; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D000093542:Gemcitabine
Disseminierte intravasale Gerinnung (DIG) und massive Hyperfibrinolyse bei metastasierendem Uteruskarzinom. Beobachtungen über die Beeinflussung der Gerinnungsstörung durch verschiedene Therapien (ein Fallbericht).